AstraZeneca (AZN) Explores $400 Billion Merger with Bristol Myers

AstraZeneca is in discussions with Bristol Myers Squibb regarding a potential merger valued at $400 billion, according to multiple reports. This significant deal could reshape the pharmaceutical landscape as both companies explore a tie-up. Such a merger may have implications for market competition and drug pricing strategies. For investors, understanding potential changes in company dynamics and market positioning is critical as developments unfold.